- Home
- PRLD vs CATO Comparison
PRLD vs CATO Comparison
Compare PRLD & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- CATO
- Stock Information
- Founded
- PRLD 2016
- CATO 1946
- Country
- PRLD United States
- CATO United States
- Employees
- PRLD N/A
- CATO N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- CATO Clothing/Shoe/Accessory Stores
- Sector
- PRLD Health Care
- CATO Consumer Discretionary
- Exchange
- PRLD Nasdaq
- CATO Nasdaq
- Market Cap
- PRLD 73.7M
- CATO 63.9M
- IPO Year
- PRLD 2020
- CATO N/A
- Fundamental
- Price
- PRLD $0.81
- CATO $2.45
- Analyst Decision
- PRLD Strong Buy
- CATO
- Analyst Count
- PRLD 2
- CATO 0
- Target Price
- PRLD $4.50
- CATO N/A
- AVG Volume (30 Days)
- PRLD 279.1K
- CATO 80.4K
- Earning Date
- PRLD 05-06-2025
- CATO 05-22-2025
- Dividend Yield
- PRLD N/A
- CATO 13.96%
- EPS Growth
- PRLD N/A
- CATO N/A
- EPS
- PRLD N/A
- CATO N/A
- Revenue
- PRLD $7,000,000.00
- CATO $649,806,000.00
- Revenue This Year
- PRLD N/A
- CATO N/A
- Revenue Next Year
- PRLD N/A
- CATO N/A
- P/E Ratio
- PRLD N/A
- CATO N/A
- Revenue Growth
- PRLD N/A
- CATO N/A
- 52 Week Low
- PRLD $0.61
- CATO $2.19
- 52 Week High
- PRLD $6.80
- CATO $6.70
- Technical
- Relative Strength Index (RSI)
- PRLD 57.52
- CATO 38.68
- Support Level
- PRLD $0.71
- CATO $2.19
- Resistance Level
- PRLD $0.72
- CATO $2.97
- Average True Range (ATR)
- PRLD 0.08
- CATO 0.27
- MACD
- PRLD 0.02
- CATO -0.07
- Stochastic Oscillator
- PRLD 76.92
- CATO 16.35
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.